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OBJECTIVES: Hyponatremia has been associated with increased length of stay (LOS) 
in patients hospitalized for heart failure (HF). To date, little has been reported about 
the impact of pharmacologic intervention for hyponatremia on hospital LOS in this 
patient population. We evaluated the impact of tolvaptan, a new oral non-peptide 
vasopressin antagonist versus standard of care (SOC) on the index hospitalization LOS 
in patients with HF and concomitant hyponatremia in the EVEREST (Efﬁcacy of  
Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) multina-
tional Phase 3 trial. METHODS: A post-hoc analysis of covariance (ANCOVA) was 
performed on the hyponatremic subset of EVEREST. Both bivariate and multivariate     
analyses were conducted to account for regional variation attributed to the multina-
tional study design. Separate analyses were conducted according to patients’ admission        
serum sodium (135 mEq/L and 130 mEq/L). The model was adjusted for treatment      
as a factor and both region and treatment and region interaction term as covariates. 
Signiﬁcance was assessed with student’s t-test at (p  0.05). RESULTS: In patients 
with admission serum sodium 135 mEq/L, those receiving tolvaptan (n  225) had 
an adjusted LOS 1.72 days shorter than those receiving SOC (n  216) (p  0.061). 
In more severely hyponatremic patients (130 mEq/L), tolvaptan patients (n  21) had 
an adjusted LOS 2.12 days shorter than those receiving SOC (n  48) (p  0.581). 
Although not signiﬁcant due to small cell size, these trends in reduced index hospital-
ization LOS with tolvaptan use remained consistent in both the bivariate and multi-
variate analyses. CONCLUSIONS: Use of tolvaptan in hyponatremic patients 
hospitalized for heart failure may be associated with a decrease in hospital LOS com-
pared to SOC treatment. Larger studies, particularly in severely hyponatremic HF        
populations, are necessary to conﬁrm the statistical signiﬁcance of a LOS difference 
of this magnitude.
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OBJECTIVES: The goal of this study was to determine whether initiation of warfarin 
treatment in patients with atrial ﬁbrillation (AF), while in hospital, is associated with 
increased length of stay. METHODS: This was a prospective study involving patients 
with AF newly started on warfarin while in hospital. It was conducted in 3 acute 
medical wards (total 96 beds) of a district general hospital. Patients were reviewed 
daily regarding the necessity of their hospital stay. Their stay was considered delayed 
if their original medical condition had resolved and their stay was attributed solely to 
initiation of warfarin to reach a therapeutic International Normalized Ratio (INR). 
The Barthel Index score was used to assess patients’ activities of daily living. The 
medical teams treating these patients were unaware of the objective of the study. 
RESULTS: Over a 6-month period 23 patients with AF (13 men, 10 women; mean 
[SD] age, 75.4 [9.2] years) were started on warfarin while in hospital and thus com-
prised our study group. Of these 23 patients, 7 (30%) had delayed discharges that 
were solely attributed to initiation of warfarin. Total length of stay for all patients 
combined was 217 days; of these, 36 (17%) days were considered delayed discharges. 
Only 10 (43%) patients were discharged with their INR in the target range of 2 to 3. 
There was no signiﬁcant difference between patients who had delayed discharges 
versus non delayed discharges in terms of age, sex, number of comorbidities, number 
of medications, Barthel Index score, reason for admission, mean INR, number of 
patients achieving target INR on discharge, or warfarin loading regimens. CONCLU-
SIONS: Initiation of warfarin in these patients with AF while in the hospital led to 
increased length of stay. A move toward starting anticoagulation in an outpatient 
setting could reduce length of hospital stay.
CARDIOVASCULAR DISORDERS – Patient-Reported Outcomes Studies
PCV129
METHODOLOGY TO ASSESS THE IMPACT OF POOR COMPLIANCE 
WITH COMMON TREATMENTS
Meszaros A, Truman P
University of York, York, UK
OBJECTIVES: Poor-compliance with medicines is commonly recognised amongst 
health care practitioners, and is associated with economic and health consequences. 
By not using prescribed medicines optimally, patients are essentially wasting health 
service resources that could be put to effective use elsewhere. Our aim was to evaluate 
the economic/patient impact arising from poor compliance with commonly used 
medications. Economic models were developed for several studies to examine the 
impact of non-compliance on patient outcomes and health care resource consumption 
within the NHS. METHODS: Case studies included hypertension, high cholesterol/
coronary heart disease, and diabetes. The selection of case studies considered, condi-
tions which are treated with high volumes of low and high cost drugs and the signiﬁ-
cant volume of unused medicines was reported. For each of the studies a decisin 
analytic model was developed, intending to reﬂect the treatment pathways and patient 
outcomes associated with treatment. Event rates for relevant endpoints were derived 
from clinical trial evidence. For the events considered, cost was derived from published 
literature. Treatment costs were calculated using unit costs from the British National 
Formulary; in case of multiple therapeutic options, treatment cost was based on the 
most widely used intervention, or the intervention on which event rates were based. 
Utility values for patients were also derived from the literature to allow estimates of 
the loss of quality of life of individuals. RESULTS: Diabetes (compliance vs. partial 
noncompliance): £128.35, 0.02; Hypertension (compliance vs. partial compliance): 
£121.70, 0.03; Hypertension (compliance vs. non compliance): £167.85, 0.06; 
Hypercholesterolemia (compliance vs. partial compliance): £133.18, 0.04; Hypercho-
lesterolemia (compliance vs. non compliance): £135.73, 0.05 for incremental costs 
(per-patient), incremental utilities (per-patient). CONCLUSIONS: The results conﬁrm 
that resources are wasted and there is signiﬁcant loss in quality of life with partial 
(non)compliance. It is hoped that the approaches developed in this research might be 
suitable for further development and application to a wider range of conditions.
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OBJECTIVES: To compare different methods of assessing adherence to antihyperten-
sive (AHT) therapy, since some methods may be confounded by differences in persis-
tence. METHODS: Australian Pharmaceutical Beneﬁts Scheme (PBS) claims data 
provided by Medicare Australia has been used to assess compliance to AHT therapy. 
This analysis is based on all scripts supplied to a one in ten sample of the Australian 
patient population drawn from de-identiﬁed PBS payment records from June 2003 to 
June 2005. PBS prescriptions for most AHT products are for 28 or 30 days supply. 
Concessional patients newly initiated to; dihydropyridine (DHP) Calcium Channel 
Blockers (CCB), angiotensin two receptor antagonists (A2RA) and angiotensin con-
verting enzyme inhibitors (ACE), were identiﬁed and the following compliance infor-
mation determined: number of scripts dispensed in the 12 months post initiation; 
average time between reﬁlls; median medication possession ratio (MPR) and median 
persistence. RESULTS: More than 85,000 Australian Concessional patients were initi-
ated on these AHT products. Assessment of compliance (adherence) found the interval 
between reﬁlls for AHTs was 34 days or less for 75% of patients and median MPRs 
exceeded 90% (considered compliant), yet the mean number of scripts collected in 
365 days was only 8.0 per patient (considered non compliant) There were large dif-
ferences between AHT products. Mean intervals between reﬁlls ranged from 28 
(trandolapril) to 44 (captopril) days, while average scripts per patient per year ranged 
from 3.8 (captopril) to 8.8 (lercanidipine). Median persistence to the molecule ranged 
from 2 months (captopril) to 19 months (lercanidipine). CONCLUSIONS: Using 
scripts counts over a year period to assess patient compliance may be misleading. 
Intervals between reﬁlls suggest that most patients are compliant if they collect their 
prescriptions.
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OBJECTIVES: To characterise the effect of upper gastrointestinal (GI) symptoms on 
nonadherence and discontinuation of low-dose acetylsalicylic acid (ASA; aspirin) in 
patients with cardiovascular (CV) risk. METHODS: This observational study (Clini-
calTrials.gov identiﬁer: NCT00681759; AstraZeneca study code: D961FC00004), 
conducted at 77 centres in USA, Canada and France, included patients q18 years at 
risk of or with CV disease, about to begin or previously prescribed daily low-dose 
ASA (75–325 mg) within 5 years. Nonadherence (75% of low-dose ASA taken) and 
discontinuation (no low-dose ASA use for 7 continuous days) were assessed using 3 
months prospective data collected by eDiary q3 times/day. RESULTS: 340 patients 
(mean age 50 years; 59% women) were assessed; 65% needed low-dose ASA for sec-
ondary or high-risk primary CV prevention, and 35% for lower-risk primary preven-
tion. Most (75%) were low-dose ASA-naïve at inclusion, with no upper GI symptoms 
within the previous 14 days. Overall, 18% of patients were nonadherent. Adherence 
was negatively inﬂuenced by upper GI (odds ratio [OR] 0.84; 95% CI 0.70, 1.00; 
p  .05) and dyspeptic (OR 0.81; 95% CI 0.66, 1.00; p  0.05) symptoms. Low-dose 
ASA-naïve patients at inclusion had the greatest risk of nonadherence associated with 
upper GI episodes (OR 0.76; 95% CI 0.57, 1.00; p  0.05). Overall, 13% of patients 
discontinued low-dose ASA therapy. Upper GI symptoms were associated with an 
increased risk of discontinuation (hazard ratio [HR] 1.1; 95% CI 1.0, 1.2; p  0.01). 
Discontinuation risk increased with more frequent upper GI symptoms, overall and 
in low-dose ASA-naïve patients. Among the latter, patients experiencing GI symptoms 
q 3 times during the preceding week had       7 times the risk of discontinuation than 
